 |
|
Adult Bone Marrow–Derived Cells for Cardiac RepairA Systematic Review and Meta-analysis
Ahmed Abdel-Latif, MD;
Roberto Bolli, MD;
Imad M. Tleyjeh, MD, MSc;
Victor M. Montori, MD, MSc;
Emerson C. Perin, MD;
Carlton A. Hornung, PhD, MPH;
Ewa K. Zuba-Surma, PhD;
Mouaz Al-Mallah, MD;
Buddhadeb Dawn, MD
Arch Intern Med. 2007;167(10):989-997.
Background The results from small clinical studies suggest that therapy with adult bone marrow (BM)–derived cells (BMCs) reduces infarct size and improves left ventricular function and perfusion. However, the effects of BMC transplantation in patients with ischemic heart disease remains unclear.
Methods We searched MEDLINE, EMBASE, Science Citation Index, CINAHL (Cumulative Index to Nursing and Allied Health), and the Cochrane Central Register of Controlled Trials (CENTRAL) (through July 2006) for randomized controlled trials and cohort studies of BMC transplantation to treat ischemic heart disease. We conducted a random-effects meta-analysis across eligible studies measuring the same outcomes.
Results Eighteen studies (N = 999 patients) were eligible. The adult BMCs included BM mononuclear cells, BM mesenchymal stem cells, and BM-derived circulating progenitor cells. Compared with controls, BMC transplantation improved left ventricular ejection fraction (pooled difference, 3.66%; 95% confidence interval [CI], 1.93% to 5.40%; P<.001); reduced infarct scar size (–5.49%; 95% CI, –9.10% to –1.88%; P = .003); and reduced left ventricular end-systolic volume (–4.80 mL; 95% CI, –8.20 to –1.41 mL; P = .006).
Conclusions The available evidence suggests that BMC transplantation is associated with modest improvements in physiologic and anatomic parameters in patients with both acute myocardial infarction and chronic ischemic heart disease, above and beyond conventional therapy. Therapy with BMCs seems safe. These results support conducting large randomized trials to evaluate the impact of BMC therapy vs the standard of care on patient-important outcomes.
Author Affiliations: Division of Cardiology and the Institute of Molecular Cardiology (Drs Abdel-Latif, Bolli, Zuba-Surma, and Dawn) and Department of Epidemiology and Population Health, School of Public Health and Information Sciences (Dr Hornung), University of Louisville, Louisville, Ky; Knowledge and Encounter Research Unit, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minn (Drs Tleyjeh and Montori); King Fahd Medical City, Riyadh, Saudi Arabia (Dr Tleyjeh); Department of Cardiology, University of Texas, Houston (Dr Perin); and Division of Cardiovascular Imaging, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (Dr Al-Mallah).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study
Funaro et al.
Eur Heart J 2008;0:ehn529v1-10.
ABSTRACT
| FULL TEXT
Insights into mechanisms behind arteriogenesis: what does the future hold?
van Oostrom et al.
J. Leukoc. Biol. 2008;84:1379-1391.
ABSTRACT
| FULL TEXT
"B2 or not B2?": Kinin Receptors and Endothelial Progenitor Cell Dysfunction
Ward et al.
Circ. Res. 2008;103:1202-1203.
FULL TEXT
From Genes to Regenerative Medicine: Approaches in Development
Ruel et al.
Circ. Res. 2008;103:1050-1052.
FULL TEXT
Collagen-Based Matrices Improve the Delivery of Transplanted Circulating Progenitor Cells: Development and Demonstration by Ex Vivo Radionuclide Cell Labeling and In Vivo Tracking With Positron-Emission Tomography
Zhang et al.
Circ Cardiovasc Imaging 2008;1:197-204.
ABSTRACT
| FULL TEXT
Clinical trials in stem cell transplantation: guidelines for scientific and ethical review
Lo et al.
Clin Trials 2008;5:517-522.
ABSTRACT
Pilot Trial on Determinants of Progenitor Cell Recruitment to the Infarcted Human Myocardium
Schachinger et al.
Circulation 2008;118:1425-1432.
ABSTRACT
| FULL TEXT
A Factor Underlying Late-Phase Arrhythmogenicity After Cell Therapy to the Heart: Global Downregulation of Connexin43 in the Host Myocardium After Skeletal Myoblast Transplantation
Coppen et al.
Circulation 2008;118:S138-S144.
ABSTRACT
| FULL TEXT
Concise Review: Mesenchymal Stromal Cells: Potential for Cardiovascular Repair
Psaltis et al.
Stem Cells 2008;26:2201-2210.
ABSTRACT
| FULL TEXT
Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review
Martin-Rendon et al.
Eur Heart J 2008;29:1807-1818.
ABSTRACT
| FULL TEXT
Erythropoietin and mesenchymal stromal cells in angiogenesis and myocardial regeneration: one plus one equals three?
Ward and Stewart
Cardiovasc Res 2008;79:357-359.
FULL TEXT
Review: Endothelial progenitor cells: markers of vascular reparative capacity
Povsic and Goldschmidt-Clermont
Ther Adv Cardiovasc Dis 2008;2:199-213.
ABSTRACT
Transplantation of Bone Marrow-Derived Very Small Embryonic-Like Stem Cells Attenuates Left Ventricular Dysfunction and Remodeling After Myocardial Infarction
Dawn et al.
Stem Cells 2008;26:1646-1655.
ABSTRACT
| FULL TEXT
An Inconvenient Truth: Recognizing Individual Differences in Arteriogenesis
Rehman
Circ. Res. 2008;102:1146-1147.
FULL TEXT
The Stem Cell Movement
Smart and Riley
Circ. Res. 2008;102:1155-1168.
ABSTRACT
| FULL TEXT
The Management of Heart Failure: The Past, the Present, and the Future
Braunwald
Circ Heart Fail 2008;1:58-62.
FULL TEXT
Noncanonical Wnt11 Signaling Is Sufficient to Induce Cardiomyogenic Differentiation in Unfractionated Bone Marrow Mononuclear Cells
Flaherty et al.
Circulation 2008;117:2241-2252.
ABSTRACT
| FULL TEXT
Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction: A Meta-Analysis
Zohlnhofer et al.
J Am Coll Cardiol 2008;51:1429-1437.
ABSTRACT
| FULL TEXT
The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial: First Randomized Placebo-Controlled Study of Myoblast Transplantation
Menasche et al.
Circulation 2008;117:1189-1200.
ABSTRACT
| FULL TEXT
Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases
Burt et al.
JAMA 2008;299:925-936.
ABSTRACT
| FULL TEXT
|
